541 related articles for article (PubMed ID: 18398615)
1. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults.
Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS
Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults.
Petain A; Kattygnarath D; Azard J; Chatelut E; Delbaldo C; Geoerger B; Barrois M; Séronie-Vivien S; LeCesne A; Vassal G;
Clin Cancer Res; 2008 Nov; 14(21):7102-9. PubMed ID: 18981009
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors.
Delbaldo C; Chatelut E; Ré M; Deroussent A; Séronie-Vivien S; Jambu A; Berthaud P; Le Cesne A; Blay JY; Vassal G
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6073-8. PubMed ID: 17062683
[TBL] [Abstract][Full Text] [Related]
4. Use of total and unbound imatinib and metabolite LC-MS/MS assay to understand individual responses in CML and GIST patients.
Streit F; Binder L; Hafke A; Brandhorst G; Braulke F; Haase D; Armbrust T; Cameron S; Ramadori G; Oellerich M; Walson P
Ther Drug Monit; 2011 Oct; 33(5):632-43. PubMed ID: 21912334
[TBL] [Abstract][Full Text] [Related]
5. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.
Teng JF; Mabasa VH; Ensom MH
Ther Drug Monit; 2012 Feb; 34(1):85-97. PubMed ID: 22215488
[TBL] [Abstract][Full Text] [Related]
6. Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome.
Beumer JH; Natale JJ; Lagattuta TF; Raptis A; Egorin MJ
Pharmacotherapy; 2006 Jul; 26(7):903-7. PubMed ID: 16803422
[TBL] [Abstract][Full Text] [Related]
7. Effect of St John's wort on imatinib mesylate pharmacokinetics.
Frye RF; Fitzgerald SM; Lagattuta TF; Hruska MW; Egorin MJ
Clin Pharmacol Ther; 2004 Oct; 76(4):323-9. PubMed ID: 15470331
[TBL] [Abstract][Full Text] [Related]
8. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
Cohen MH; Williams G; Johnson JR; Duan J; Gobburu J; Rahman A; Benson K; Leighton J; Kim SK; Wood R; Rothmann M; Chen G; U KM; Staten AM; Pazdur R
Clin Cancer Res; 2002 May; 8(5):935-42. PubMed ID: 12006504
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
Golabchifar AA; Rezaee S; Ghavamzadeh A; Alimoghaddam K; Dinan NM; Rouini MR
Cancer Chemother Pharmacol; 2014 Jul; 74(1):85-93. PubMed ID: 24817601
[TBL] [Abstract][Full Text] [Related]
10. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients.
Gambacorti-Passerini C; Zucchetti M; Russo D; Frapolli R; Verga M; Bungaro S; Tornaghi L; Rossi F; Pioltelli P; Pogliani E; Alberti D; Corneo G; D'Incalci M
Clin Cancer Res; 2003 Feb; 9(2):625-32. PubMed ID: 12576428
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.
Widmer N; Decosterd LA; Csajka C; Leyvraz S; Duchosal MA; Rosselet A; Rochat B; Eap CB; Henry H; Biollaz J; Buclin T
Br J Clin Pharmacol; 2006 Jul; 62(1):97-112. PubMed ID: 16842382
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
Guo F; Letrent SP; Sharma A
Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.
Peng B; Hayes M; Resta D; Racine-Poon A; Druker BJ; Talpaz M; Sawyers CL; Rosamilia M; Ford J; Lloyd P; Capdeville R
J Clin Oncol; 2004 Mar; 22(5):935-42. PubMed ID: 14990650
[TBL] [Abstract][Full Text] [Related]
14. Metabolism and disposition of imatinib mesylate in healthy volunteers.
Gschwind HP; Pfaar U; Waldmeier F; Zollinger M; Sayer C; Zbinden P; Hayes M; Pokorny R; Seiberling M; Ben-Am M; Peng B; Gross G
Drug Metab Dispos; 2005 Oct; 33(10):1503-12. PubMed ID: 16006570
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk.
Russell MA; Carpenter MW; Akhtar MS; Lagattuta TF; Egorin MJ
J Perinatol; 2007 Apr; 27(4):241-3. PubMed ID: 17377606
[TBL] [Abstract][Full Text] [Related]
16. Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec).
Gordon JK; Magid SK; Maki RG; Fleisher M; Berman E
Leuk Res; 2010 Jun; 34(6):827-9. PubMed ID: 19963273
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study.
Pappas P; Karavasilis V; Briasoulis E; Pavlidis N; Marselos M
Cancer Chemother Pharmacol; 2005 Oct; 56(4):358-60. PubMed ID: 15883819
[TBL] [Abstract][Full Text] [Related]
18. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype.
Gurney H; Wong M; Balleine RL; Rivory LP; McLachlan AJ; Hoskins JM; Wilcken N; Clarke CL; Mann GJ; Collins M; Delforce SE; Lynch K; Schran H
Clin Pharmacol Ther; 2007 Jul; 82(1):33-40. PubMed ID: 17495881
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia.
Boddy AV; Sludden J; Griffin MJ; Garner C; Kendrick J; Mistry P; Dutreix C; Newell DR; O'Brien SG
Clin Cancer Res; 2007 Jul; 13(14):4164-9. PubMed ID: 17634544
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
Wen PY; Yung WK; Lamborn KR; Dahia PL; Wang Y; Peng B; Abrey LE; Raizer J; Cloughesy TF; Fink K; Gilbert M; Chang S; Junck L; Schiff D; Lieberman F; Fine HA; Mehta M; Robins HI; DeAngelis LM; Groves MD; Puduvalli VK; Levin V; Conrad C; Maher EA; Aldape K; Hayes M; Letvak L; Egorin MJ; Capdeville R; Kaplan R; Murgo AJ; Stiles C; Prados MD
Clin Cancer Res; 2006 Aug; 12(16):4899-907. PubMed ID: 16914578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
